Pfizer’s $70 billion deal with the U.S. government is essentially a Pay-Off
By Lance D Johnson
Post on October 3, 2025
As Pfizer basks in record-breaking profits from its COVID-19 vaccine—now the most lucrative pharmaceutical product in history—the company has quietly secured a golden shield against accountability for the problems that vaccine caused. In a stunning move, Pfizer has pledged $70 billion in U.S. investments and steep Medicaid price cuts in exchange for preferential treatment under Trump’s “most favored nation” (MFN) drug pricing scheme. This deal effectively immunizes Pfizer from tariffs and scrutiny while locking the U.S. government into a long-term dependency on its products. Meanwhile, thousands of vaccine-injured Americans are left without justice as Pfizer executives, like CEO Albert Bourla, evade indictment for ignoring and downplaying early warnings of serious harm with their experimental vaccine.
This isn’t just corporate maneuvering—it’s a calculated escape from liability. By embedding itself into government healthcare programs, Pfizer ensures its dominance over the medical industry while sidestepping responsibility for the injuries and deaths linked to its mRNA shots. With full FDA approval and aggressive marketing campaigns, Pfizer now pushes its vaccines on children as young as five, despite unresolved safety concerns. The company’s $2.8 billion advertising budget floods news networks like CNN and ABC, shaping public perception while suppressing unfavorable side effect disclosures.
The truth is clear: Pfizer isn’t just profiting from a scam of epic, coercive proportions—it’s profiting from the suffering it helped create. And with the U.S. government now financially tethered to Pfizer’s discounted drugs, the pharmaceutical giant has rendered itself untouchable.
Key points:
- Pfizer’s COVID vaccine generated $37.8 billion in 2022, with profits soaring into the “high 20s” margin.
- The company secured a three-year tariff exemption and government favoritism in exchange for $70 billion in U.S. investments and Medicaid price cuts.
- Pfizer dominates 74% of the U.S. vaccine market, pushing its shots on children despite concerns over natural immunity and adverse events.
- Aggressive marketing partnerships with major news networks suppress negative coverage of vaccine injuries.
- The Trump administration’s MFN deal locks Pfizer into government healthcare programs, ensuring long-term profits while shielding the company from liability.
Pfizer’s vaccine windfall and the cost of silence
Pfizer’s financial success is staggering—but it comes at a devastating human cost. The company’s mRNA vaccine, developed with BioNTech, has become a cash cow, raking in $13 billion in just one quarter. Yet, buried beneath the earnings reports are thousands of reports of severe adverse reactions, including myocarditis, blood clots, and autoimmune disorders. Despite this, Pfizer enjoys near-total legal immunity under the Public Readiness and Emergency Preparedness (PREP) Act, which shields vaccine manufacturers from lawsuits during declared health emergencies.
Now, with the MFN deal, Pfizer has further insulated itself from accountability. By offering steep discounts on Medicaid drugs and funneling billions into U.S. production, the company has bought political goodwill—ensuring that regulators turn a blind eye to mounting evidence of vaccine harm. This isn’t philanthropy; it’s a calculated business move. As Pfizer’s stock surges, injured patients struggle to find doctors willing to acknowledge their suffering, let alone hold the company responsible.
Marketing the narrative: How Pfizer controls the media
Pfizer’s influence extends far beyond government deals. The company sponsors major news programs like Good Morning America, Anderson Cooper 360°, and CNN Tonight, ensuring favorable coverage while sidelining critical voices through shadow banning and demonetization strategies coordinated through social media platforms. By avoiding direct vaccine advertisements, Pfizer bypasses FDA-mandated side effect disclosures—keeping the public in the dark about risks.
This media manipulation mirrors Big Pharma’s past tactics, such as Purdue Pharma’s covert funding of opioid advocacy groups. The result? A carefully crafted narrative that portrays Pfizer as a savior while dismissing vaccine injuries as “rare” or “coincidental.” Meanwhile, independent researchers and whistleblowers face censorship, their findings buried under a flood of pharmaceutical-funded propaganda. In this deception, Pfizer remains unscathed and even praised, while bringing previous critics like Secretary Kennedy to heel, as Kennedy helped secure the $70 billion deal that made Pfizer look compassionate, innocent.
The MFN trap: How Pfizer bought its innocence
The Trump administration’s MFN policy was marketed as a win for consumers—but in reality, it’s a lifeline for Pfizer. By agreeing to price cuts on older drugs, the company secures guaranteed sales through Medicaid and TrumpRx.gov, a new federal direct-to-consumer platform. This ensures a steady revenue stream while Pfizer pushes its newer, pricier treatments—including COVID boosters and gene therapies—onto an unsuspecting public. Albert Bourla was giddy at the press conference in front of President Trump, Dr. Oz, and Secretary Kennedy. He mentioned that Pfizer will now be freed up to work on new mRNA jabs for cancer (completely disregarding the failures of the COVID mRNA jabs). Now, Bourla will have direct access to consumers through Trump’s new direct-to-consumer platform.
This deal also grants Pfizer a three-year reprieve from tariffs, effectively rewarding the company for past misconduct. While injured families fight for recognition for their vaccine injury and the death of their loved ones, Pfizer executives laugh all the way to the bank and look like the saviors once again. The message is clear: In America’s broken healthcare system, profits trump justice—and Pfizer has mastered the game.
Lance D Johnson
